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Abstract 
XRCC4-like factor (XLF), also known as Cernunnos, is a protein encoded by the human NHEJ1 
gene and an important repair factor for DNA double-strand breaks. In this study, we have found 
that XLF is over-expressed in HPV(+) versus HPV(-) head and neck squamous cell carcinoma 
(HNSCC) and significantly down-regulated in the HNSCC cell lines expressing high level of mutant 
p53 protein versus those cell lines harboring wild-type TP53 gene with low p53 protein expression. 
We have also demonstrated that Werner syndrome protein (WRN), a member of the NHEJ 
repair pathway, binds to both mutant p53 protein and NHEJ1 gene promoter, and siRNA 
knockdown of WRN leads to the inhibition of XLF expression in the HNSCC cells. Collectively, 
these findings suggest that WRN and p53 are involved in the regulation of XLF expression and the 
activity of WRN might be affected by mutant p53 protein in the HNSCC cells with aberrant TP53 
gene mutations, due to the interaction of mutant p53 with WRN. As a result, the expression of 
XLF in these cancer cells is significantly suppressed. Our study also suggests that XLF is 
over-expressed in HPV(+) HNSCC with low expression of wild type p53, and might serve as a 
potential biomarker for HPV(+) HNSCC. Further studies are warranted to investigate the 
mechanisms underlying the interactive role of WRN and XLF in NHEJ repair pathway. 
Key words: XLF, mutant p53, biomarker, HPV, HNSCC  
Introduction 
Non-homologous end joining (NHEJ) is a 
well-known mechanism for the repair of 
double-strand breaks (DSBs), a lethal type of DNA 
damage in mammalian cells. It basically utilizes a 
group of enzymes to take hold of the ends of a broken 
DNA molecule, create a bridge between them, and 
subsequently re-ligate the broken DNA molecule [1]. 
Ku heterodimer (KU70/KU80), DNA-dependent 
protein kinase catalytic subunit (DNA PKcs), DNA 
repair protein XRCC4 (X-ray repair cross- 
complementing protein 4) and DNA Ligase IV 
constitute the core elements of the NHEJ apparatus. 
The repair process is initiated by binding of the 
ring-shaped Ku70/Ku80 heterodimer (Ku) to both 
ends of a DSB, followed by recruitment of DNA PKcs 
to the DNA-Ku complex. The DNA Ligase IV, a 
specialized DNA ligase that forms a complex with the 
cofactor XRCC4, then directly joins the two ends of a 
DSB. NHEJ remains active throughout the cell cycle, 
but is the major DSB repair mechanism during the G1 
phase of the cell cycle. It is also the primary repair 
pathway for DSBs induced by radiation damage. 
XRCC4-like factor (XLF), also known as 
Cernunnos, is a protein encoded by the human NHEJ1 
gene and originally discovered as a molecule mutated 
in patients with growth retardation, microcephaly, 
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and immunodeficiency [2]. The interaction of XLF 
with XRCC4 is required for the NHEJ repair of DSBs 
[3-5]. Studies have shown that XLF can bind to DNA 
and accumulated at DNA damage sites via 
constitutive interaction of XRCC4 in the early DSB. 
XLF may also stimulate ligation of complementary 
and non-complementary DNA ends by combining 
with XRCC4-DNA Ligase IV complex, enhancing the 
stability of XRCC4-DNA ligase IV, modulating the 
efficiency and/or specificity of DNA Ligase IV and 
promoting the Ligase IV activity in the later of DSB. In 
XLF-deficiency murine embryonic stem (ES) cells, 
there are serious defects as observed in XLF/Cer 
patients, including radiation sensitivity, intrinsic DSB 
repair defect, and increased genomic instability with 
elevated levels of chromosomal breaks and 
translocations in comparison to wild type ES cells. 
These results indicated that XLF/Cer plays an 
important role in the NHEJ process for DNA repair [6, 
7]. Nevertheless, little is known about the cellular 
machinery that regulates the expression of XLF in 
mammalian cells, particularly at transcriptional 
regulation level. 
Werner syndrome protein (WRN) is a member of 
the human RecQ family DNA helicases implicated in 
the maintenance of genome stability. Mutations of the 
WRN gene give rise to the Werner syndrome, a 
genetic disease characterized by premature aging and 
cancer predisposition [8]. Patients carrying WRN gene 
mutations also exhibit increased genomic instability 
and an elevated rate of cancer [9, 10]. WRN may play 
an important role in NHEJ because it strongly binds to 
Ku and is recruited to DNA ends by Ku [11-13]. In 
fact, Ku stimulates/alters the properties of WRN 
exonuclease activity on a variety of DNA substrates 
[14], and DNA-PKcs phosphorylates WRN and 
regulates its catalytic activity as well [15, 16]. 
Moreover, the WRN protein can form a specific 
interaction with tumor suppressor p53. This 
interaction involves the carboxyl-terminal part of 
WRN and the extreme carboxyl terminus of p53, a 
region that plays an important role in the functional 
state of p53. Over-expression of WRN leads to 
augmented p53-dependent transcriptional activity 
and induction of p21 protein expression. These 
findings imply that the cross talk between WRN and 
p53 may be important for maintaining genomic 
integrity and for preventing the accumulation of 
aberrations that can give rise to premature senescence 
and cancer [17]. 
In this study, we found that XLF and mutant p53 
expression levels are inversely correlated in head and 
neck cancer cells. When compared to HPV(-) 
HNSCCs, XLF is over-expressed in HPV(+) HNSCCs, 
which normally harbor wild-type TP53 and express 
low levels of p53 protein. We also found that WRN 
binds to both mutant p53 and the NHEJ1 gene 
promoter, and siRNA knockdown of WRN leads to 
the inhibition of XLF expression in the cancer cells. 
Collectively, these findings suggest that WRN is 
potentially involved in the regulation of XLF 
expression and the activity of WRN may be affected 
by mutant p53 protein in the head and neck cancer 
cells with aberrant TP53 gene mutations, due to the 
interaction of mutant p53 with WRN. As a result, the 
expression of XLF in these cancer cells was 
significantly inhibited.  
Materials and Methods 
Cell culture 
The head and neck cancer cell lines, UM1, UM2, 
UMSCC-5, UMSCC-6, UMSCC-10B, and UMSCC-17B 
cell lines were obtained from Dr. Yong Kim 
(University of California, Los Angeles, School of 
Dentistry). All the cancer cell lines were cultured in 
DMEM with 10% fetal bovine serum and 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, CA, 
USA). Normal human oral keratinocytes (NHOK) 
were cultured in EpiLife media supplemented with 
the human keratinocyte growth supplement 
(Invitrogen, Carlsbad, CA, USA). Cell cultures were 
maintained in a humidified atmosphere of 5% CO2 at 
37 °C.  
2-Dgel electrophoresis (2-DGE) analysis 
HNSCC tissues were used for the present study 
following the provision of the UCLA Institutional 
Review Board approval. Prior to 2-DGE analysis, 
snap-frozen cancer tissues were lysed with 2-D 
rehydration buffer containing 2M thiourea, 7M urea, 
2% CHAPS and 50mM DTT, and the total protein 
concentration was measured with the 2D Quant kit 
(GE Healthcare). Due to small amount of tissue 
materials available, 2-DGE analysis was performed on 
two pooled cancer tissue samples (HPV(+) or HPV(-) 
HNSCCs, total amount of 75µg each), which were 
prepared by equally pooling of tissue lysates from 
each individual subjects (equal amount of total 
proteins). The pooled samples were initially 
processed with 2-D Clean-up Kit (GE Healthcare) to 
remove interfering small molecules present in the 
samples. Afterwards, both pooled samples (60 µg 
from each sample) were focused withimmobilized pH 
gradient strips (11-cm length, pI 3-10 NL) on a Protean 
IEF cell and then separated with 8-16 % Criterion 
SDS-PAGE gels (Bio-Rad). Finally, the PAGE gels 
were stained with fluorescent Sypro-Ruby stain 
(Invitrogen) and gel images were acquired with the 
GS-800 gel imager (BioRad). 
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Analysis of gel images was performed using the 
Progenesis Samespot software (Nonlinear dynamics). 
A matchset was created initially, and protein spots 
were automatically matched and further manually 
verified. Afterwards, normalization was performed 
based on the total density of the gel image and the 
proteins levels were quantified. Each protein sample 
was analyzed in triplicate and Student T-test was 
used for statistical analysis. 
Liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) 
 Protein spots of interest were excised using a 
spot-excision robot (Progenesis) and deposited into 
96-well plates. Tryptic digestion of proteins in each 
gel spots were performed by first reducing protein 
with 10 mM DTT for 30 min, followed by alkylation 
with 50 mMiodoacetamide for 60 min in the dark, and 
then digested with 10-ng trypsin at 37°C overnight. 
The resulting peptides were extracted and analysed 
by LC-MS/MS using a nano-LC system (Eksigent 
Technology) and LTQ ion trap mass spectrometer 
(Thermo Finnigan). LC separation of peptides was 
performed with C18 PicoFrit capillary columns (New 
Objectives) at a flow rate of 400nL/min. Database 
search was performed against the SwissProt database 
using the Proteome Discoverer/SEQUEST (Thermo 
Finnigan).  
Western blotting 
Cell lysates (30µg total proteins of each sample) 
were separated with a 12% NuPAGE gel (Invitrogen) 
at 120V for approximately 60 min and then 
transferred to nitrocellulose membrane using the 
TRANS-BLOT semi-dry transfer cell (Bio-Rad). 
Membranes were blocked with 5% milk in TBST 
buffer (1×) for 2 hours and then incubated with a 
primary antibody overnight at 4°C. The following 
primary antibodies, anti-XLF (Sigma, St. Louis, MO), 
anti-WRN (Santa Cruz Biotech, Dallas, TX), and 
anti-p53 (Genetex, Irvine, CA), were used for Western 
blot analysis. Following incubation with secondary 
antibody horseradish peroxidase-conjugated mouse 
or rabbit antibody (GE Healthcare, NJ, USA), protein 
bands were detected using the ECL Kit (GE 
Healthcare).  
Chromatin immunoprecipitation (ChIP) 
ChIP assays were performed with the ChIP assay 
kit from Millipore (Cat # 17-295, Billerica, MA, USA). 
After washing with PBS, the cancer cells were 
cross-linked with 1% formaldehyde for 15 min at 
room temperature and then stopped by adding 125 
mM glycine. Cells were then washed twice with cold 
PBS, harvested in RIPA buffer (150 mM NaCl, 1% 
Igepal CA-630, 0.5% deoxycholate, 0.1% SDS, 50 mM 
Tris-HCl at pH 8), and sonicated to generate DNA 
fragments between 200 and 1000 base pairs. For 
immunoprecipitation, 1 mg of protein extract was 
pre-cleared with 30 μL of Protein A Agarose/Salmon 
Sperm DNA (50% Slurry) for 30min. Once the agarose 
centrifuged and removed, the supernatant fraction 
was incubated with 5μg of WRN antibody (Santa 
Cruz Biotechnology) overnight at 4°C and then 
incubated with 30μL Protein A Agarose/Salmon 
Sperm DNA (50% Slurry) for one hour at 4°C. 
Following the washes with low salt, high salt, LiCl 
immune complex wash buffers as well as the TE 
buffer, the immunocomplexes were harvested, eluted 
with 1%SDS/0.1M NaHCO3 for 10 min at 65°C, and 
then treated with NaCl (200mM) at 65°C for 4 hours to 
reverse histone-DNA crosslinks. Finally, the DNA 
fragments were purified and used as templates for 
qPCR reactions using the following primers: 
GTGGGAAAGGCTTTATGCAA (forward) and 
TCCCATAGTCCGACCTCATC (reverse).  
Co-immunoprecipitation (Co-IP)  
MyOne Dynabeads (Invitrogen) were first 
coated with the WRN antibody (Santa Cruz Biotech) 
according to the manufacturer’s suggested protocol. 
Afterwards, the coated beads were washed twice in 
PBS/0.1% BSA (pH 7.4) for 5 minutes at 4° C, and then 
incubated in 0.2M Tris/0.2% BSA (pH 8.5) for 24 
hours at 4° C. Cancer cells were collected using a Cell 
Stripper (Cellgro, Mediatech, Manassas, VA) and 
washed extensively with PBS for three times, followed 
by re-suspension in RIPA buffer. The supernatant 
(2mg total proteins) was transferred and incubated 
with the antibody-coated Dynabeads at 4 °C for 
overnight, followed by extensive washes with PBS. 
The beads were then harvested and citric acid (100 
mM, pH 2.9) was added to elute the proteins from the 
beads. Afterwards, the eluted samples were tested for 
p53 with Western blotting.  
siRNA knockdown of WRN 
To perform siRNA knockdown of WRN, UM1, 
UM2, UM-SCC5 and UM-SCC6 cells were transfected 
with targeted siRNA to WRN (Santa Cruz Biotech) 
using the Hilymax transfection regent (Dojindo 
Molecular Technologies, Rockville, MD) according to 
the company’s suggested manual. Validated 
double-stranded siRNAs of WRN or non-target 
scramble control siRNAs were mixed with the 
Hilymax transfection reagent and then added to the 
cell cultures. After 24-hour incubation, the media 
containing siRNAs were removed and the cells were 
further cultured in fresh complete media for 48 hours 
prior to cell harvesting for Western blot analysis. 
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Sequencing of TP53 gene in UM1 and UM2 cell 
lines 
DNA was extracted from UM1 and UM2 cells 
using the QIAamp DNA Mini kits (Qiagen, Hilden, 
Germany). TP53 exons was polymerase chain reaction 
(PCR) amplified from each sample using the 
following set of primers: primer set 1 - forward 
TCTCATGCTGGATCCCCACTT; reverse ACGGCCA
GGCATTGAAGTCTCAT; primer set 2 - forward 
CTCTTCCTACAGTACTCCCCTGC; reverse GGCCA
CTGACAACCACCCTTAACC; primer set 3 - forward 
ACCTGATTTCCTTACTGCCTCTTGC; reverse CCA
CTTGATAAGAGGTCCCAAG. PCR products were 
purified with the DNA Clean and Concentrator Kit 
(Zymo Research, Irvine, CA) and sequenced on an 
ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems, Foster City, CA). DNA sequences were 
first viewed as chromatograms using the Finch TV. 
Using the program, the sequences amplified by 
reverse primers were converted to reverse 
complements, and then exported as FASTA files. The 
exported sequences were aligned to their respective 
p53 sequences obtained from NCBI gene (Accession 
number NC_000017.11, Gene ID 7157) using the 
EMBOSS Water Nucleotide Alignment Tool. The 
ExPASy Translate Tool was used to determine amino 
acid sequences based on the mutant sequence, and the 
wild type and mutated amino acid sequences were 
aligned using the EMBOSS Water Protein Alignment 
Tool. 
Results  
Identification of differentially expressed 
proteins between HPV(+) and HPV(-) 
HNSCCs 
Figure 1 shows 2-D gel analysis of proteins 
expressed in HPV(+) and HPV(-) HNSCC tissues. 
Following gel staining with Sypro Ruby, proteins 
showing differential expression levels were excised 
from the gels and identified with LC-MS/MS. Table 1 
presents a list of identified proteins that are 
differentially expressed between HPV(+) and HPV(-) 
HNSCCs. XLF, a DNA repair protein, was found to be 
over-expressed in HPV(+) HNSCCs when compared 
to HPV(-) HNSCCs. 
 
Table 1. Differentially expressed proteins between HPV(+) and 
HPV(-) HNSCCs. 
Protein name PI MW 
(kDa) 
Up- or 
down-regulation 
Ratio 
HPV(+):HPV(-) 
ADP-ribosylation factor 4 7.02 20.5 Up-regulation 4.1 
Ferritin-like protein 5.27 20.0 Up-regulation 2.7 
Galectin-1 5.15 14.1 Up-regulation 2.7 
Heat shock protein beta 1 5.97 22.8 Up-regulation 3.0 
Isoform 1 of gelsolin 5.86 49.2 Up-regulation 2.4 
Peroxiredoxin-6 5.97 25.0 Up-regulation 3.0 
Prohibitin 5.46 29.8 Up-regulation 1.3 
PARK7 protein 8.36 21.8 Up-regulation 5.2 
Superoxide dismutase 5.95 25.1 Up-regulation 4.5 
XRCC4-like factor (XLF) 6.25 19.6 Up-regulation 5.3 
Annexin A1 6.64 38.7 Down-regulation 0.6 
Cystatin A 5.26 11.0 Down-regulation 0.1 
Fatty acid binding protein 6.79 15.2 Down-regulation 0.3 
Fibrinogen beta chain 8.23 55.9 Down-regulation 0.1 
Isoform 1 of 14-3-3 protein 
sigma  
4.53 27.8 Down-regulation 0.2 
Serpin B4 5.82 44.9 Down-regulation 0.4 
 
 
 
Figure 1. 2-DGE of proteins in HPV(+) and HPV(-) HNSCC tissues. Equal amount of tissue proteins from 5 HPV-positive or 5 HPV-negative HNSCC patients were 
pooled for the comparative analysis. Differentially expressed proteins were identified and listed in Table 1. Protein identity: Spot #1: Heat shock protein beta 1; Spot 
#2: PARK7 protein; Spot #3: XRCC4-like factor (XLF); Spot #4: Superoxide dismutase (SOD).  
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Expression of mutant p53 and XLF in head and 
neck cancer cells 
Using Western blotting, we measured the 
expression of p53, XLF and WRN in NHOKs, two 
wild type TP53 HNSCC lines, UM-SCC6 and 
UM-SCC17B, as well as two mutant TP53 HNSCC 
lines, UM-SCC5 and UM-SCC10B. As expected, 
mutant TP53 HNSCC lines displayed a dramatic 
over-expression of p53 versus wild type TP53 HNSCC 
lines which had very low p53 expression (Figure 2A). 
On the other hand, XLF expression was found to be 
much lower in mutant TP53 HNSCC lines versus wild 
type TP53 HNSCC lines.  
We also compared the expression of p53, WRN 
and XLF betweenUM1 and UM2 oral cancer cell lines 
which were initially established from a same patient’s 
tumor. UM1 cells are highly invasive whereas UM2 
cells are low invasive. Our invasion assay results 
indicate that UM1 cells have more than 8-fold 
invasive potential than UM2 cells (data not shown). 
As shown in Figure 2B, both p53 and XLF expression 
levels are not significantly different between UM1 and 
UM 2 cells.  
Sequencing of TP53 gene in UM1 and UM2 
cells 
The mutation sites of TP53 in UMSCC-5 and 
UMSCC-10B cells have been identified previously 
[18]. However, whether the TP53 gene in UM1 and 
UM2 cells is wild type or mutant remains to be a 
question. By using PCR to amplify the TP53 gene and 
subsequently sequence the amplified DNA, we found 
that the TP53 gene in UM1 and UM2 cells has single 
point mutation at codon 72 on exon 4, where a 
Guanine replaces Cytidine in the wild type TP53 
sequence (Figure 3). This CCC → CGC mutation 
causes a change from Proline to Arginine in p53 
protein sequence in UM1 and UM2 cells. The single 
point mutations of TP53 among the four cell lines are 
listed in Table 2.  
Table 2. TP53 mutations of head and neck cancer cell lines in this 
study. 
Cell line Codon change Amino acid change Reference 
UM1 72 CCC ⇒ CGC P ⇒ R Current study 
UM2 72 CCC ⇒ CGC P ⇒ R Current study 
UM-SCC5 157 GTC ⇒ TTC V ⇒ F [1] 
UM-SCC10B 245 GGC ⇒ TGC G ⇒ C [1] 
UM-SCC6 Wild type N/A [1] 
UM-SCC17B Wild type N/A [1] 
 
WRN binds to the NHEJ1 promoter  
To test if WRN binds to the promoter of NHEJ1 
gene, we performed the ChIP assay of UM1 and UM2 
cells using anti-WRN antibody, followed by qPCR 
using primers for the promoter region of NHEJ1. As 
shown in Figure 4A, Results from the ChIP assay 
indicated that endogenous WRN binds to the NHEJ1 
gene promoter in UM1 and UM2 cells.  
Binding of mutant p53 to WRN 
To verify if mutant p53 protein interacts with 
WRN in HSNCC cells, we performed Co-IP assay 
with the protein lysates from UMSCC-5 and 
UMSCC-10B. Both UMSCC-5 and UMSCC-10B 
express high levels of mutant p53. As shown in Figure 
4B, mutant p53 was co-immunoprecipitated by the 
anti-WRN antibody.  
siRNA knockdown of WRN leads to 
down-regulation of XLF 
To further explore if WRN has a potential role in 
regulating XLF expression, we knocked down WRN 
using siRNA and confirmed the reduced expression 
of WRN in the cancer cells. As shown in Figure 5, 
siRNA inhibition of WRN expression led to the 
down-regulation of XLF in the head and neck cancer 
cells.  
 
 
Figure 2. (A) Western blot analysis of p53, WRN and XLF in wild-type and mutant TP53 head and neck squamous cell carcinoma (HNSCC) cells. (B) Western blot 
analysis of p53, WRN and XLF between UM1 and UM2 oral cancer cells.  
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Figure 3. Sequencing of TP53 gene in UM1 (top) and UM2 (bottom) oral cancer cells. Comparison between wild-type and UM1/UM2 TP53 gene shows a C to G 
transversion in both UM1 and UM2 cells, occurring at codon 72. As indicated by the alignment, the single nucleotide mutation causes the change of proline (P) in 
wild-type TP53 gene to arginine (R) in UM1 and UM2 cells at codon 72.  
 
 
Figure 4. (A) ChIP assay suggests that WRN may bind to the upstream 
promoter region of NHEJ1 in UM1 and UM2 oral cancer cells. Shown here is 
qPCR of the pull-down products from ChIP assays. (B) Co-IP assay suggests that 
mutant p53 binds to WRN in UM-SCC5 and UM-SCC10B cells. Western 
blotting was used to detect p53 in whole cell lysates, anti-WRN pull-down and 
negative control samples. 
 
Discussion  
In this study, we first compared tissue protein 
expression between HPV(+) and HPV(-) HNSCCs 
using 2-DGE and then identified the proteins that are 
altered in HPV(+) HNSCCs with LC-MS/MS. As 
shown in Table 1, a number of proteins are 
differentially expressed between the two cancer tissue 
phenotypes suggesting that HPV(+) HNSCC cells 
may contain unique proteome profile characteristic of 
viral oncogenic transformation. Particularly, we 
found that XLF, an important factor of the NHEJ 
repair process, is over-expressed in HPV(+) HNSCCs 
when compared to HPV(-) HNSCCs. It is well known 
that HPV(+) HNSCCs harbor wild-type TP53 gene 
and the expression of p53 is low due to E6-associated 
degradation [19, 20]. Therefore, we compared the 
expression levels of XLF and p53 between wild type 
(UM-SCC6 and UM-SCC17B) and mutant TP53 
(UM-SCC5 and UM-SCC10B) HNSCC cell lines. As 
expected, p53 expression is substantially low in the 
cancer cells with wild type TP53 gene. However, 
mutant TP53 HNSCC lines displayed a dramatic 
over-expression of p53 when compared to wild-type 
HNSCC lines (Figure 2A). The TP53 is one of the most 
frequent mutated genes in tumors, with more than 
half of all human cancers displaying some forms of 
mutations at this gene locus, and most of the TP53 
mutations are missense forms that mainly reside in 
the region coding for the DNA binding domain [21]. 
The relationship between tobacco use and insurgence 
of HNSCC strongly suggest that mutation of TP53 is 
one hallmark genetic alteration of these tumors [22]. 
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Unlike wild-type p53, which is generally a highly 
controlled, short-lived protein under stressed 
conditions, mutated forms of TP53 often lead to the 
accumulation of full length mutant p53 molecules 
with a prolonged half-life [23]. In contrast to a 
majority of tumor suppressor genes, which are mostly 
inactivated as a result of a mutation, mutant p53 has 
been shown to obtain gain-of-function oncogenic 
activity aside from the normal role of wild-type p53, 
and may promote metastatic potential of tumor cells. 
From a variety of studies, it becomes apparent 
mutations in TP53 are connected to the poor response 
of HNSCC to anticancer therapy [24-27]. Mice 
knocked in with p53R270H or R172H, corresponding 
to the human hotspot mutants p53R273H and 
p53R175H, respectively, developed highly metastatic 
tumors [28, 29]. Recent studies also demonstrated that 
mutant p53 can augment cell migration and invasion 
in in vitro assays [21, 30, 31]. Both UM-SCC5 and 
UM-SCC10B cell lines used in our study carry TP53 
point mutations within the DNA-binding domain 
[18]. These mutations caused significant accumulation 
of mutant p53 with prolonged half-life in the 
UM-SCC5 and UM-SCC10B cells, which explains why 
p53 levels are dramatically high in these cells. On the 
other hand, XLF expression was found to be 
significantly lower in mutant TP53 HNSCC lines 
(UM-SCC5 and UM-SCC10B) versus wild-type TP53 
HNSCC lines (UM-SCC6 and UM-SCC17B), 
suggesting that there is an inverse correlation 
between the expression of mutant p53 and XLF.  
We also compared the expression of p53 and XLF 
between highly invasive UM1 and low invasive UM2 
oral cancer cell lines. Both p53 and XLF are similarly 
expressed between the two cell lines, which 
presumably is due to that the two cell lines were 
derived from a same patient’s tumor. Our sequencing 
analysis indicates that there is a C→G transversion at 
codon position 72 of TP53 gene in both UM1 and UM2 
cells, which caused the replacement of proline with 
arginine for the protein. This single nucleotide 
polymorphism is located in the proline rich region but 
not within the central region of DNA-binding domain 
(codon 101-306), which is the target of 90% of p53 
mutations found in human cancers. Many studies 
have investigated the genetic link between this 
variation and cancer susceptibility; however, the 
results have been controversial. For instance, TP53 
codon 72 polymorphism was associated with an 
increased risk of lung cancer [32] and renal cell 
carcinoma [33]. However, meta-analyses failed to 
show significant associations between TP53 codon 72 
polymorphisms with cervical cancer [34], colorectal 
cancer [35] and endometrial cancer [36]. Nevertheless, 
this single variation may not be sufficient to 
completely impair p53 function in UM1 and UM2 
cells, and certainly not as oncogenic as mutant TP53 
found in UM-SCC5 and UM-SCC10B cells which 
contain mutations within the DNA-binding domain.  
Our studies suggest that WRN may be involved 
in the regulation of XLF expression in HNSCC cells. 
The ChIP assay results indicate that WRN binds to the 
NHEJ1 gene promoter in UM1 and UM2 cells. This is 
not surprising considering that WRN is a RecQ-like 
helicase which unwinds double-stranded DNA to 
facilitate DNA replication or gene transcription. In 
addition, knockdown of WRN in head and neck 
cancer cells led to the down-regulation of XLF 
expression. These findings seem to imply that WRN 
may be involved in the regulation of NHEJ1 gene 
expression in HNSCC cells. In fact, previous studies 
have shown that WRN has a role in RNA polymerase 
II-dependent gene transcription. WRN functionally 
interacts with rRNA and unwind not only a duplex 
DNA but also an RNA-DNA heteroduplex [37-39]. 
Furthermore, DNA microarray analysis indicates that 
WRN protein, by virtue of its helicase and 
transcription-activating activities, as well as its 
protein interactions, is directly or indirectly involved 
in the transcription of genes upstream in the network 
of aging pathways [40]. Collectively, these previous 
findings indicate involvement of WRN in 
 
Figure 5. siRNA knockdown of WRN leads to the down-regulation of XLF in HNSCC cells. WRN and XLF were measured by Western blot analysis.  
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transcription and suggest that decreased transcription 
rate might be a cause of premature aging phenotypes 
observed in WS patients [40].  
Although there has been no evidence on its 
direct regulation of XLF expression, p53 may be 
involved in this regulatory process through its 
interaction with WRN. The binding of mutant p53 to 
WRN has been well demonstrated in previous studies 
and shown to inhibit WRN exonuclease/ATPase 
activity [41, 42]. Our Co-IP results further confirm that 
mutant p53 protein (V157F and G245C, UM-SCC5 and 
UM-SCC10B cells) binds to WRN and may downplay 
the functional role of WRN. In UM-SCC5 and 
UM-SCC10B cells, the mutant p53 expression levels 
are substantially high, which may partially deactivate 
the function of WRN due to its strong binding to 
WRN. Consequently, the expression of XLF is 
significantly inhibited, which might explain the 
inverse relationship between p53 and XLF expression 
levels in the HNSCC cells.  
As a summary, we have found WRN may be 
involved in the regulation of XLF, an important DSB 
repair factor, in HNSCC cells. We have also found 
that XLF is over-expressed in HPV(+) versus HPV(-) 
HNSCCs and significantly down-regulated in 
HNSCC cells expressing high level of mutant p53 
when compared to the HNSCC cells harboring 
wild-type TP53. This may be due to the binding of 
mutant p53 to WRN protein, partially inactivating the 
function of WRN and therefore down-regulating the 
expression of XLF. However, in HNSCC cells 
harboring wild-type TP53, p53 protein expression is 
very low and therefore may not affect the activity of 
WRN. In the future, we plan to knock out or knock 
down the expression of mutant p53 in the HNSCC cell 
lines harboring mutant TP53 gene, and further verify 
if down-regulation of mutant p53 leads to the 
over-expression of XLF in the HNSCC cells. 
Nevertheless, the physiologic role of XLF in NHEJ 
pathway has been well established, and its 
down-regulation is known to cause a defect in DSB 
repair. Our findings suggest there is a possible 
interplay of WRN/p53 on the regulation of XLF 
expression, and provide additional insight regarding 
the role of mutant p53 and WRN in NHEJ process.  
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